12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

FluMist Quadrivalent regulatory update

FDA approved FluMist Quadrivalent from AstraZeneca's MedImmune LLC subsidiary to prevent seasonal influenza in people ages 2-49 years. FDA said...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >